106 related articles for article (PubMed ID: 2510514)
21. Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B.
Tross S; Herndon J; Korzun A; Kornblith AB; Cella DF; Holland JF; Raich P; Johnson A; Kiang DT; Perloff M; Norton L; Wood W; Holland JC
J Natl Cancer Inst; 1996 May; 88(10):661-7. PubMed ID: 8627642
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs.
Buzdar AU; Hortobagyi GN; Smith TL; Kau S; Marcus C; Holmes FA; Hug V; Fraschini G; Ames FC; Martin RG
Cancer; 1988 Nov; 62(10):2098-104. PubMed ID: 3179922
[TBL] [Abstract][Full Text] [Related]
23. Acute arterial thrombosis during adjuvant Adriamycin-cyclophosphamide chemotherapy in a patient with early breast cancer: A case report.
Jang LC; Choi YJ
Medicine (Baltimore); 2019 Dec; 98(50):e18249. PubMed ID: 31852092
[TBL] [Abstract][Full Text] [Related]
24. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
25. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Ploner F; Jakesz R; Hausmaninger H; Kolb R; Stierer M; Fridrik M; Steindorfer P; Gnant M; Haider K; Mlineritsch B; Tschurtschenthaler G; Steger G; Seifert M; Kubista E; Samonigg H;
Onkologie; 2003 Apr; 26(2):115-9. PubMed ID: 12771518
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
Livi L; Saieva C; Borghesi S; De Luca Cardillo C; Scotti V; Mangoni M; Greto D; Cataliotti L; Paiar F; Bianchi S; Biti GP
J Chemother; 2009 Nov; 21(5):558-65. PubMed ID: 19933048
[TBL] [Abstract][Full Text] [Related]
27. The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.
Nolan L; Darby A; Boleti K; Simmonds P
Breast; 2011 Apr; 20(2):151-4. PubMed ID: 20970333
[TBL] [Abstract][Full Text] [Related]
28. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
[TBL] [Abstract][Full Text] [Related]
29. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
[TBL] [Abstract][Full Text] [Related]
30. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
31. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
32. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
[TBL] [Abstract][Full Text] [Related]
33. Secondary acute myelocytic leukemia after adjuvant therapy for early-stage breast carcinoma. A new complication of cyclophosphamide, methotrexate, and 5-fluorouracil therapy.
Geller RB; Boone LB; Karp JE; Davidson N; Selonick SE; Edwards J; Burke PJ
Cancer; 1989 Aug; 64(3):629-34. PubMed ID: 2743258
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.
Buzdar AU; Hortobagyi GN; Kau SW; Smith TL; Fraschini G; Holmes FA; Gutterman JU; Hug VM; Singletary SE; Ames FC
J Clin Oncol; 1992 Oct; 10(10):1540-6. PubMed ID: 1403033
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of metastatic breast cancer].
Yahalom J; Biran S; Sulkes A
Harefuah; 1986 Jul; 111(1-2):8-11. PubMed ID: 2430868
[No Abstract] [Full Text] [Related]
36. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.
Levine MN; Gent M; Hryniuk WM; Bramwell V; Abu-Zahra H; DePauw S; Arnold A; Findlay B; Levin L; Skillings J
J Clin Oncol; 1990 Jul; 8(7):1217-25. PubMed ID: 2193119
[TBL] [Abstract][Full Text] [Related]
38. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
39. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
[TBL] [Abstract][Full Text] [Related]
40. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
